Compare National Beverage Corp. (FIZZ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs ResMed Inc. — how do they compare? National Beverage Corp. trades at $31.95 (market cap $2.89B), while ResMed Inc. trades at $202.12 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 10× National Beverage Corp.'s market cap, and ResMed Inc. pays a 1.21% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | RMD | |
|---|---|---|
Market Cap | $2.89B | $28.80B |
Sector | Consumer Cyclical | Health |
52-Week High | $47.69 | $293.73 |
52-Week Low | $30.85 | $182.82 |
Enterprise Value | $2.60B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $32.09, up 3.78% on the day, but the stock faces bearish technical signals and mixed earnings results, with three of the last four quarters missing EPS estimates. The company maintains solid profitability with a 15.56% net income margin and a 34.03% ROE, while a recent special dividend of $3.25 per share reflects shareholder returns. However, revenue has stagnated around $1.2 billion annually, and analyst sentiment is cautious, with 50% of coverage recommending Sell.
The outlook for FIZZ is clouded by stalled growth and competitive pressures, particularly for its LaCroix brand. While valuation multiples like a P/E of 15.73 appear reasonable, the lack of revenue catalysts and bearish technical trends suggest limited near-term upside. Key risks include declining volumes and consumer weakness, requiring investors to weigh dividend returns against fundamental headwinds.
ResMed (RMD) trades at $201.44, up 4.37% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 27.44% net margins and consistent revenue growth from $3.6B in 2022 to $5.15B in 2025. Recent strategic moves include divesting MatrixCare for $490M to sharpen focus on core sleep and respiratory care markets.
RMD presents a compelling growth story with analyst consensus pointing to 28% upside potential to $245.88. However, technical weakness and competitive pressures in the medical device space warrant caution. The company's strong cash flow generation and dividend payments provide shareholder value, but investors should monitor execution risks from the business portfolio restructuring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
